In the assessment of 12-month price targets, analysts unveil insights for Globus Medical, presenting an average target of $90 ...

Truist lowered the firm’s price target on Globus Medical (GMED) to $80 from $82 and keeps a Hold rating on the shares as part of a broad ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical ...

GMED recently completed its previously disclosed acquisition of Nevro Corp., a global medical device company that delivers ...

In a report released today, Mathew Blackman from Stifel Nicolaus maintained a Buy rating on Beta Bionics, Inc. (BBNX – Research Report), with a ...

Globus Medial completed its acquisition of Nevero, a spinal cord stimulator company, according to an April 3 news release.

Globus Medical (NYSE:GMED) announced today that that it completed its previously announced acquisition of Nevro.

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its ...

Globus Medical GMED has outperformed the market over the past 10 years by 1.08% on an annualized basis producing an average annual return of 11.62%. Currently, Globus Medical has a market ...

Learn more about whether Globus Medical, Inc. or Inspire Medical Systems, Inc. is a better investment based on AAII's A+ ...